Literature DB >> 32078373

Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation.

M Benjamin Shoemaker1, Daniela Husser2, Carolina Roselli3, Meelad Al Jazairi4, Jonathan Chrispin5, Michael Kühne6,7, Benjamin Neumann8, Stacey Knight9,10, Han Sun11, Sanghamitra Mohanty12,13, Christian Shaffer1, Sébastien Thériault14,15, Lauren Lee Rinke1, Joylene E Siland4, Diane M Crawford1, Laura Ueberham2, Omeed Zardkoohi16, Petra Büttner2, Bastiaan Geelhoed4, Steffen Blum6,7, Stefanie Aeschbacher6,7, Jonathan D Smith17, David R Van Wagoner18, Rebecca Freudling8,19, Martina Müller-Nurasyid19,20, Jay Montgomery1, Zachary Yoneda1, Quinn Wells1, Tariq Issa1, Peter Weeke1, Victoria Jacobs9, Isabelle C Van Gelder4, Gerhard Hindricks2, John Barnard11, Hugh Calkins5, Dawood Darbar21, Greg Michaud1, Stefan Kääb8,20, Patrick Ellinor3,22, Andrea Natale12,13,23,24,25, Mina Chung16, Saman Nazarian26, Michael J Cutler27, Moritz F Sinner8,20, David Conen6,7,14, Michiel Rienstra4, Andreas Bollmann2, Dan M Roden28, Steven Lubitz3,22.   

Abstract

BACKGROUND: Ablation is a widely used therapy for atrial fibrillation (AF); however, arrhythmia recurrence and repeat procedures are common. Studies examining surrogate markers of genetic susceptibility to AF, such as family history and individual AF susceptibility alleles, suggest these may be associated with recurrence outcomes. Accordingly, the aim of this study was to test the association between AF genetic susceptibility and recurrence after ablation using a comprehensive polygenic risk score for AF.
METHODS: Ten centers from the AF Genetics Consortium identified patients who had undergone de novo AF ablation. AF genetic susceptibility was measured using a previously described polygenic risk score (N=929 single-nucleotide polymorphisms) and tested for an association with clinical characteristics and time-to-recurrence with a 3 month blanking period. Recurrence was defined as >30 seconds of AF, atrial flutter, or atrial tachycardia. Multivariable analysis adjusted for age, sex, height, body mass index, persistent AF, hypertension, coronary disease, left atrial size, left ventricular ejection fraction, and year of ablation.
RESULTS: Four thousand two hundred seventy-six patients were eligible for analysis of baseline characteristics and 3259 for recurrence outcomes. The overall arrhythmia recurrence rate between 3 and 12 months was 44% (1443/3259). Patients with higher AF genetic susceptibility were younger (P<0.001) and had fewer clinical risk factors for AF (P=0.001). Persistent AF (hazard ratio [HR], 1.39 [95% CI, 1.22-1.58]; P<0.001), left atrial size (per cm: HR, 1.32 [95% CI, 1.19-1.46]; P<0.001), and left ventricular ejection fraction (per 10%: HR, 0.88 [95% CI, 0.80-0.97]; P=0.008) were associated with increased risk of recurrence. In univariate analysis, higher AF genetic susceptibility trended towards a higher risk of recurrence (HR, 1.08 [95% CI, 0.99-1.18]; P=0.07), which became less significant in multivariable analysis (HR, 1.06 [95% CI, 0.98-1.15]; P=0.13).
CONCLUSIONS: Higher AF genetic susceptibility was associated with younger age and fewer clinical risk factors but not recurrence. Arrhythmia recurrence after AF ablation may represent a genetically different phenotype compared to AF susceptibility.

Entities:  

Keywords:  atrial fibrillation; genetic variation; genetics; phenotype; pulmonary veins

Mesh:

Year:  2020        PMID: 32078373      PMCID: PMC7080569          DOI: 10.1161/CIRCEP.119.007676

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  34 in total

1.  Pitx2c and Nkx2-5 are required for the formation and identity of the pulmonary myocardium.

Authors:  Mathilda T M Mommersteeg; Nigel A Brown; Owen W J Prall; Corrie de Gier-de Vries; Richard P Harvey; Antoon F M Moorman; Vincent M Christoffels
Journal:  Circ Res       Date:  2007-09-06       Impact factor: 17.367

2.  Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation.

Authors:  Moritz F Sinner; Nathan R Tucker; Kathryn L Lunetta; Kouichi Ozaki; J Gustav Smith; Stella Trompet; Joshua C Bis; Honghuang Lin; Mina K Chung; Jonas B Nielsen; Steven A Lubitz; Bouwe P Krijthe; Jared W Magnani; Jiangchuan Ye; Michael H Gollob; Tatsuhiko Tsunoda; Martina Müller-Nurasyid; Peter Lichtner; Annette Peters; Elena Dolmatova; Michiaki Kubo; Jonathan D Smith; Bruce M Psaty; Nicholas L Smith; J Wouter Jukema; Daniel I Chasman; Christine M Albert; Yusuke Ebana; Tetsushi Furukawa; Peter W Macfarlane; Tamara B Harris; Dawood Darbar; Marcus Dörr; Anders G Holst; Jesper H Svendsen; Albert Hofman; Andre G Uitterlinden; Vilmundur Gudnason; Mitsuaki Isobe; Rainer Malik; Martin Dichgans; Jonathan Rosand; David R Van Wagoner; Emelia J Benjamin; David J Milan; Olle Melander; Susan R Heckbert; Ian Ford; Yongmei Liu; John Barnard; Morten S Olesen; Bruno H C Stricker; Toshihiro Tanaka; Stefan Kääb; Patrick T Ellinor
Journal:  Circulation       Date:  2014-08-14       Impact factor: 29.690

3.  Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life.

Authors:  Spyridon Deftereos; Georgios Giannopoulos; Michael Efremidis; Charalampos Kossyvakis; Apostolos Katsivas; Vasiliki Panagopoulou; Charalampos Papadimitriou; Sofia Karageorgiou; Konstantinos Doudoumis; Konstantinos Raisakis; Andreas Kaoukis; Dimitrios Alexopoulos; Antonis S Manolis; Christodoulos Stefanadis; Michael W Cleman
Journal:  Heart Rhythm       Date:  2014-02-04       Impact factor: 6.343

Review 4.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

5.  Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Authors:  Anna Gundlund; Emil Loldrup Fosbøl; Sunghee Kim; Gregg C Fonarow; Bernard J Gersh; Peter R Kowey; Elaine Hylek; Kenneth W Mahaffey; Laine Thomas; Jonathan P Piccini; Eric D Peterson
Journal:  Am Heart J       Date:  2016-02-18       Impact factor: 4.749

6.  Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation.

Authors:  Lu-Chen Weng; Sarah R Preis; Olivia L Hulme; Martin G Larson; Seung Hoan Choi; Biqi Wang; Ludovic Trinquart; David D McManus; Laila Staerk; Honghuang Lin; Kathryn L Lunetta; Patrick T Ellinor; Emelia J Benjamin; Steven A Lubitz
Journal:  Circulation       Date:  2017-11-12       Impact factor: 29.690

7.  Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation.

Authors:  Seung Hoan Choi; Lu-Chen Weng; Carolina Roselli; Honghuang Lin; Christopher M Haggerty; M Benjamin Shoemaker; John Barnard; Dan E Arking; Daniel I Chasman; Christine M Albert; Mark Chaffin; Nathan R Tucker; Jonathan D Smith; Namrata Gupta; Stacey Gabriel; Lauren Margolin; Marisa A Shea; Christian M Shaffer; Zachary T Yoneda; Eric Boerwinkle; Nicholas L Smith; Edwin K Silverman; Susan Redline; Ramachandran S Vasan; Esteban G Burchard; Stephanie M Gogarten; Cecelia Laurie; Thomas W Blackwell; Gonçalo Abecasis; David J Carey; Brandon K Fornwalt; Diane T Smelser; Aris Baras; Frederick E Dewey; Cashell E Jaquish; George J Papanicolaou; Nona Sotoodehnia; David R Van Wagoner; Bruce M Psaty; Sekar Kathiresan; Dawood Darbar; Alvaro Alonso; Susan R Heckbert; Mina K Chung; Dan M Roden; Emelia J Benjamin; Michael F Murray; Kathryn L Lunetta; Steven A Lubitz; Patrick T Ellinor
Journal:  JAMA       Date:  2018-12-11       Impact factor: 56.272

8.  Atrial Fibrillation Genetic Risk and Ischemic Stroke Mechanisms.

Authors:  Steven A Lubitz; Owen E Parsons; Christopher D Anderson; Emelia J Benjamin; Rainer Malik; Lu-Chen Weng; Martin Dichgans; Cathie L Sudlow; Peter M Rothwell; Jonathan Rosand; Patrick T Ellinor; Hugh S Markus; Matthew Traylor
Journal:  Stroke       Date:  2017-05-03       Impact factor: 7.914

9.  Genetic Risk Prediction of Atrial Fibrillation.

Authors:  Steven A Lubitz; Xiaoyan Yin; Henry J Lin; Matthew Kolek; J Gustav Smith; Stella Trompet; Michiel Rienstra; Natalia S Rost; Pedro L Teixeira; Peter Almgren; Christopher D Anderson; Lin Y Chen; Gunnar Engström; Ian Ford; Karen L Furie; Xiuqing Guo; Martin G Larson; Kathryn L Lunetta; Peter W Macfarlane; Bruce M Psaty; Elsayed Z Soliman; Nona Sotoodehnia; David J Stott; Kent D Taylor; Lu-Chen Weng; Jie Yao; Bastiaan Geelhoed; Niek Verweij; Joylene E Siland; Sekar Kathiresan; Carolina Roselli; Dan M Roden; Pim van der Harst; Dawood Darbar; J Wouter Jukema; Olle Melander; Jonathan Rosand; Jerome I Rotter; Susan R Heckbert; Patrick T Ellinor; Alvaro Alonso; Emelia J Benjamin
Journal:  Circulation       Date:  2016-10-28       Impact factor: 39.918

10.  A variant of IL6R is associated with the recurrence of atrial fibrillation after catheter ablation in a Chinese Han population.

Authors:  Gang Wu; Mian Cheng; He Huang; Bo Yang; Hong Jiang; Congxin Huang
Journal:  PLoS One       Date:  2014-06-18       Impact factor: 3.240

View more
  8 in total

1.  Role of genetics in atrial fibrillation management.

Authors:  Michiel Rienstra; Joylene E Siland; Patrick T Ellinor
Journal:  Europace       Date:  2021-04-10       Impact factor: 5.214

Review 2.  Genetics of atrial fibrillation.

Authors:  Jitae A Kim; Mihail G Chelu; Na Li
Journal:  Curr Opin Cardiol       Date:  2021-05-01       Impact factor: 2.161

Review 3.  Genetics of atrial fibrillation-practical applications for clinical management: if not now, when and how?

Authors:  Shinwan Kany; Bruno Reissmann; Andreas Metzner; Paulus Kirchhof; Dawood Darbar; Renate B Schnabel
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 10.787

4.  Clinical characteristics and long-term outcomes of catheter ablation in young adults with atrial fibrillation.

Authors:  Michael Ghannam; Aman Chugh; David J Bradley; Thomas Crawford; Rakesh Latchamsetty; Hamid Ghanbari; Ryan Cunnane; Mohammed Saeed; Krit Jongnarangsin; Frank Pelosi; Fred Morady; Hakan Oral
Journal:  J Interv Card Electrophysiol       Date:  2021-04-05       Impact factor: 1.759

5.  Atrial fibrillation and left atrial size and function: a Mendelian randomization study.

Authors:  Yordi J van de Vegte; Joylene E Siland; Michiel Rienstra; Pim van der Harst
Journal:  Sci Rep       Date:  2021-04-19       Impact factor: 4.379

Review 6.  Identifying Atrial Fibrillation Mechanisms for Personalized Medicine.

Authors:  Brototo Deb; Prasanth Ganesan; Ruibin Feng; Sanjiv M Narayan
Journal:  J Clin Med       Date:  2021-12-01       Impact factor: 4.241

7.  Intrinsic Cellular Susceptibility to Barrett's Esophagus in Adults Born with Esophageal Atresia.

Authors:  Chantal A Ten Kate; Annelies de Klein; Bianca M de Graaf; Michail Doukas; Antti Koivusalo; Mikko P Pakarinen; Robert van der Helm; Tom Brands; Hanneke IJsselstijn; Yolande van Bever; René M H Wijnen; Manon C W Spaander; Erwin Brosens
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

8.  Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation.

Authors:  Jasmeet S Reyat; Winnie Chua; Victor R Cardoso; Anika Witten; Peter M Kastner; S Nashitha Kabir; Moritz F Sinner; Robin Wesselink; Andrew P Holmes; Davor Pavlovic; Monika Stoll; Stefan Kääb; Georgios V Gkoutos; Joris R de Groot; Paulus Kirchhof; Larissa Fabritz
Journal:  JCI Insight       Date:  2020-08-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.